Tracking development, seizures, and biomarkers over four years in children and young adults with SCN1A-related Dravet syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a four-year prospective natural-history cohort of patients aged 6 months to 21 years with a confirmed pathogenic or likely pathogenic SCN1A variant. Participants undergo a baseline visit with detailed clinical history and standardized assessments (Vineland-3, GMFM-66, CGI-S, Bayley-IV where appropriate) and an extra blood sample for metabolomics including serum GABA, then annual follow-up visits to document clinical course and repeat key measures. Eligibility requires seizure onset between 3 and 15 months, prior normal development, and current treatment with at least one listed anti-epileptic drug. The study aims to define neurodevelopmental trajectories and explore metabolomic biomarkers that correlate with clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patient or his/her legal representative must be able to give informed consent for participation in the study.
* The participant or legal representative are able (in the opinion of the investigator) to comply with the research protocol.
* Patient (male/female) between 6 months and 21 years of age inclusive at the time of consent.
* The patient has a confirmed pathogenic or probably pathogenic variant of the SCN1A gene demonstrated by a genetic test.
* The patient had normal development prior to the onset of the first seizure.
* The patient had an onset of epileptic seizures between the ages of 3 and 15 months inclusive.
* The patient is receiving at least one of the following anti-epileptic drugs prior to consent: brivaracetam, clobazam, cannabidiol, fenfluramine, levetiracetam, sodium valproate, stiripentol, topiramate

Exclusion Criteria:

* The patient has a copy number variation of the SCN1A gene affecting other genes, including a microdeletion of SCN1A.
* The patient has a mutation in the SCN1A gene on both alleles.
* The patient has a known or clinically suspected pathogenic mutation in a gene associated with epilepsy other than the SCN1A gene.
* The patient has a concomitant genetic mutation or clinical comorbidity deemed likely to disrupt the typical phenotype of Dravet syndrome.
* The patient has a known gain-of-function mutation, defined by functional studies, including p.Thr226Met.
* The patient has a history of neurodevelopmental abnormality prior to the onset of seizures, based on the medical record.
* The patient has been seizure free for a period of one year prior to informed consent.
* The patient has, at any time, taken antiepileptic drugs with a worsening effect for 6 consecutive weeks or more, including: carbamazepine, eslicarbazepine, lacosamide, lamotrigine, oxcarbazepine, phenytoin (chronic oral administration), tiagabine and vigabatrin.
* The patient has already received innovative therapies such as antisense ologonucleotides, gene therapy or cell therapy.
* The patient has a structural abnormality on brain imaging (MRI or CT scan) which the principal investigator considers to be an epileptogenic lesion.

Where it's running

• Robert Debré Hospital
  Paris, Ap-hp / DRCI, France Recruiting

Study contacts

• Principal investigator: Stéphane Auvin, MD, PhD — Assistance Publique - Hôpitaux de Paris
• Study coordinator: Stéphane Auvin, MD, PhD
• Email: stephane.auvin@aphp.fr
• Phone: 0033140032000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ION337 safety and tolerability in children with Dravet syndrome

  This will test whether ION337 is safe and well tolerated in children ages 2 to 12 with Dravet syndrome.

  Recruiting at 7 sites Phase 1/2 Ionis Pharmaceuticals, Inc. · Ann Arbor, Michigan and 6 other locations · NCT07531745

• Fintepla for Dravet Syndrome: testing brain blood flow and connections

  This study tests how Fintepla affects brain blood flow and network connections in Dravet syndrome patients who have convulsive seizures.

  Recruiting Phase 4 The University of Texas Health Science Center, Houston · Houston, Texas · NCT07112365

• PET‑MRI mapping of brainstem serotonin pathways in adults with Dravet syndrome

  This uses a PET‑MRI scan with the tracer [18F]MPPF to see if serotonin pathways in the brainstem differ in adults with Dravet syndrome compared with healthy controls.

  Recruiting Hospices Civils de Lyon · Bron, Rhone · NCT07013331

• Testing BMB-101 for Absence Epilepsy and Related Conditions

  This study is testing a new treatment called BMB-101 to see if it can help reduce seizures in people with Absence Epilepsy and related conditions.

  Recruiting at 5 sites Phase 2 Bright Minds Biosciences Pty Ltd · Randwick, New South Wales and 4 other locations · NCT06401538

• Measuring GABA Levels in Children with Dravet Syndrome

  This study is trying to measure GABA levels in the brains of children with Dravet Syndrome to see how they compare to kids without the condition, hoping to find new ways to understand and treat the syndrome.

  Recruiting Cook Children's Health Care System · Fort Worth, Texas · NCT05651204

• Evaluating ETX101 for treating Dravet syndrome in young children

  This study is testing a new treatment called ETX101 to see if it can help reduce seizures in young children with Dravet syndrome.

  Recruiting at 13 sites Phase 1/2 Encoded Therapeutics · San Francisco, California and 13 other locations · NCT05419492

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.